Balansio included as part of the cooperation between the University of Helsinki, University of Jyväskylä and one of the most prestigious Universities of China.
Quattro Folia is one of the two initial phase business partner companies which are included into the cooperation consortium between Helsinki, Jyväskylä and Shanghai Jiao Tong (SJTU) universities. The cooperation agreement signed in June promotes interaction among researchers, exchanges of researchers and training co-operation, as well as corporate co-operation in the implementation of the new healthcare solutions. The aim of the cooperation is to develop treatment and prevention methods for chronic diseases. As part of the development, the intent is to use Balansio’s clinical intelligence, regulated medical devices and the ability of supported self-care to prevent the complication of diabetes.
Shanghai Jiao Tong (SJTU) university is one of the most prestigious universities in China and under its jurisdiction, there are 13 hospitals and China's first national translational medical infrastructure centre.
Another business partner also from Finland is Nightingale Health. With the help of their mass screening blood analysis technology, chronic diseases like cardiovascular disease and diabetes can be detected early and the prevention can be monitored efficiently. The solution enables analysis of a large number of samples and it is used by the leading international universities and biobanks.
Collaborative universities represent nationally leading and internationally recognized operators in selected areas. The Finnish companies involved in the cooperation, for their part, have developed leading solutions for the research, prevention and treatment of chronic diseases. In China, there is a growing need for this kind of solutions as the chronic diseases are affecting hundreds of millions of citizens. Through the consortium, the co-operation platform is designed to connect with new projects and partners and to promote Finnish medical and health technology in China and also for the other markets.
“It is very important for Quattro Folia to be apart of the research work which with we have a common mission. The possibility of being part of this research initiative we will be able to promote modern care technology and clinical intelligence enabling the prevention of the diabetes-related complications. At the same time, we are able to develop Balansio service to be more suitable for the new markets, based on the results of the research. This is a really important opportunity to show Finnish healthcare technology and know-how, which most likely will also open new doors in the China healthcare markets.” – comments CEO of Quattro Folia, Harri Okkonen.